# DJS Antibodies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/djs-antibodies

- Industry: Biotechnology
- Headquarters: Bicester, UK
- Website: www.djsantibodies.com/
- Total disclosed funding: $8.1M
- Latest round: Seed (Dec 22, 2020)
- Investors on record: 4

## About

Based in Oxford, UK, and founded in 2014, DJS Antibodies Ltd. operates as a privately held biotechnology company that discovers and develops antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). The company was founded by David Llewellyn and Joe Illingworth. In December 2020, DJS Antibodies Ltd. raised GBP 6 million in seed funding, co-led by investors LifeArc, Amgen Ventures, and Oxford Sciences Enterprises. 

The company has developed HEPTAD, a platform for discovering antibodies, which they use to create therapeutics for the benefit of patients. DJS Antibodies utilises their exclusive HEPTAD platform for antibody discovery, particularly for challenging targets like GPCRs. The company's vision is to create therapeutics that improve the lives of people with chronic inflammatory diseases.

## Funding rounds

- Seed, Dec 22, 2020, $8.1M — Amgen Ventures, Sedgwick Funding, Oxford Sciences Enterprises, LifeArc

## Investors

- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Seed
- Sedgwick Funding — Seed
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Seed
- LifeArc (https://capitalatlas.ai/funds/lifearc) — Seed